BioTelemetry, Inc. (BEAT): Price and Financial Metrics
GET POWR RATINGS... FREE!
BEAT Stock Summary
- With a price/earnings ratio of 139.33, Biotelemetry Inc P/E ratio is greater than that of about 92.96% of stocks in our set with positive earnings.
- Price to trailing twelve month operating cash flow for BEAT is currently 23.16, higher than 76.48% of US stocks with positive operating cash flow.
- With a year-over-year growth in debt of -19.41%, Biotelemetry Inc's debt growth rate surpasses merely 15.88% of about US stocks.
- Stocks that are quantitatively similar to BEAT, based on their financial statements, market capitalization, and price volatility, are BSQR, CCF, MCRI, LXFR, and ZDGE.
- BEAT's SEC filings can be seen here. And to visit Biotelemetry Inc's official web site, go to www.gobio.com.
BEAT Stock Price Chart Interactive Chart >
BEAT Price/Volume Stats
|Current price||$71.96||52-week high||$73.10|
|Prev. close||$71.90||52-week low||$27.35|
|Day high||$72.00||Avg. volume||978,536|
|50-day MA||$67.56||Dividend yield||N/A|
|200-day MA||$49.93||Market Cap||2.47B|
BioTelemetry, Inc. (BEAT) Company Bio
BioTelemetry Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. It operates in three segments: Patient Services, Product, and Research Services. The company is based in Malvern, Pennsylvania.
BEAT Latest News Stream
|Loading, please wait...|
BEAT Latest Social Stream
View Full BEAT Social Stream
Latest BEAT News From Around the Web
Below are the latest news stories about Biotelemetry Inc that investors may wish to consider to help them evaluate BEAT as an investment opportunity.
BioTelemetry (BEAT), which is being acquired by Philips (PHG), is down 1% to $71.36 and fell more earlier after peer iRythm (IRTC) plunged after Novitas posted rates that Baird said appeared to be "really low."Novitas, a Medicare administrative contractor, posted rates that are used for reimbursement for IRTC's products."This is a...
Insights on the Telemedicine Market and Services Global Market to 2027 - Players Include BioTelemetry, Medtronic & OBS Medical Among Others
DUBLIN , Jan. 18, 2021 /PRNewswire/ -- The "Telemedicine Market and Services - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report has been added to ResearchAndMarkets.com's offering. This report on the global Telemedicine market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global Telemedicine market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global Telemedicine market during the forecast period. The report has been prepared after an extensive primary and secondary research. P...
Global MHealth Solutions Market CAGR Growth Forecast Outlook | Medtronic, Inc, Johnson & Johnson, Cerner Corporation, Omron Corporation, Cisco Systems, Inc., Biotelemetry, Inc., Ihealth Lab Inc., Sanofi, and Other
Market Research Study on MHealth Solutions Market with Industry Statistics, Trends and Forecast by 2026 Global MHealth Solutions Market report shows the Industry Chain Structure as well as Macroeconomic Environment Analysis and Development Trend. The MHealth Solutions Market report also
Is BioTelemetry, Inc.'s (NASDAQ:BEAT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
BioTelemetry (NASDAQ:BEAT) has had a great run on the share market with its stock up by a significant 60% over the last...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ALXN, MGLN, FLIR, BEAT; Shareholders Are Encouraged to Contact the Firm
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to AstraZeneca PLC for $60.00 in cash and 2.1243 AstraZeneca American Depositary Shares for each Alexion share. If you are an Alexion shareholder, click here to learn more about your rights and options.Magellan Health, Inc. (NASDAQ: MGLN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Centene Corporation for $95.00 per share in cash. If you are a Magellan shareholder, click here to learn more about y...
BEAT Price Returns